Live Breaking News & Updates on Trodelvy More

Stay updated with breaking news from Trodelvy more. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

Trodelvy More than Doubled Overall Survival as Second-Line Treatment in New ASCENT Subgroup Analysis – Gilead Sciences, Inc. today announced new data from the Phase 3 ASCENT study evaluating Trodelvy ® in relapsed or refractory metastatic triple-negative breast cancer . In this subgroup analysis of brain metastases-negative patients who received only one line of prior systemic therapy in the metastatic setting in . ....

North Carolina , United States , Foster City , Jacquie Ross , Daejin Abidoye , Alisa Carey , Nathan Kaiser , Gilead Sciences , Head Of Oncology Clinical Development , American Society Of Clinical Oncology , Breast Center , Gilead Sciences Inc , Exchange Commission , Lineberger Comprehensive Cancer Center , Gilead Public Affairs , Clinical Research , Trodelvy More , Doubled Overall Survival , Second Line Treatment , Clinical Oncology , Annual Meeting , Medical Director , North Carolina Cancer Hospital , Associate Director , Comprehensive Cancer , Important Safety ,